Jazz Pharmaceuticals (NASDAQ:JAZZ) announced Tuesday that the U.S. Food and Drug Administration (FDA) granted priority review ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

4 ZEPZELCA (lurbinectedin) for injection 4 mg, is indicated for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy. This ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS of 13.2 ...

In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. But the pair’s success leaves room for improvement for future ...

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted priority review for the supplemental New Drug Application (sNDA) for Zepzelca ...